Quetiapine
Quetiapine (Seroquel) is a second-generation antipsychotic for schizophrenia, bipolar disorder, and depression. It is not a controlled substance, but its heavy sedation drives off-label misuse as a sleep aid — a reputation that hides real dangers: QT-prolongation and heart-rhythm risk, metabolic and blood-pressure effects, and compounded respiratory depression when mixed with other CNS depressants.
Overview
Quetiapine is a second-generation, or atypical, antipsychotic, sold most widely under the brand name Seroquel, approved to treat schizophrenia, bipolar disorder and, as an adjunct, major depressive disorder. It is not a classic recreational drug and is not a controlled substance, but it is heavily sedating and is sometimes misused, often at low doses as a sleep aid and sometimes in institutional or polydrug settings, which is why it appears in a harm-reduction context. Its street reputation as a harmless sleeping pill understates its cardiac and metabolic risks.
Source: MedlinePlus; DailyMed (FDA label); StatPearls (NCBI Bookshelf)
Chemistry & mechanism of action
Quetiapine acts on multiple neurotransmitter systems, blocking dopamine D2 receptors, the basis of its antipsychotic effect, and prominently serotonin and histamine H1 receptors. Its strong antihistamine action is largely responsible for the heavy sedation and grogginess that drive its non-medical use as a sleep aid. It also blocks certain adrenergic receptors, which contributes to drops in blood pressure. This broad receptor activity explains both its therapeutic effects and its wide side-effect profile.
Source: StatPearls (NCBI Bookshelf); MedlinePlus
Effects
The most noticeable effects are strong sedation, drowsiness and calm, along with dizziness and dry mouth. Because it lowers blood pressure, standing up can cause lightheadedness or fainting, and it can affect coordination. Unlike many misused drugs it does not typically produce euphoria; the appeal is sedation. Even a single low dose can leave people heavily sedated and impaired well into the next day.
Source: MedlinePlus; DailyMed (FDA label)
Risks & harms
Although quetiapine is not a controlled substance, it is not benign. Its labeling carries warnings about a range of serious effects: it can prolong the heart's QT interval and, particularly in overdose or when combined with other QT-prolonging drugs, contribute to dangerous heart-rhythm disturbances. Atypical antipsychotics as a class raise the risk of high blood sugar, diabetes and significant weight gain with ongoing use, and can cause dangerous drops in blood pressure and falls. Rare but serious reactions include neuroleptic malignant syndrome, a life-threatening reaction with high fever and rigidity, and low white-blood-cell counts. Because quetiapine is a strong sedative, combining it with other central nervous system depressants such as alcohol, opioids or benzodiazepines compounds sedation and respiratory depression and can be dangerous. Its calming reputation masks these risks. Stopping abruptly after regular use can cause withdrawal-like effects such as nausea, insomnia and rebound symptoms, so it is generally tapered under medical guidance. Overdose can cause profound sedation, low blood pressure and heart-rhythm problems and warrants urgent care. If someone is unresponsive, having a seizure, or showing an irregular heartbeat, call 911; Poison Control at 1-800-222-1222 can advise on suspected overdoses. This page has not yet been medically reviewed.
Source: DailyMed (FDA label); StatPearls (NCBI Bookshelf); MedlinePlus
Legal status (US)
In the United States, quetiapine is a prescription-only medication but is not a controlled substance; it is not placed in any DEA schedule, reflecting that it is not considered to carry the abuse and dependence potential that scheduling addresses. It is nonetheless a prescription drug, so manufacturing, distributing or possessing it without a valid prescription is unlawful, and it is regulated as a prescription medicine in other countries as well. Follow a prescriber's directions and local law; consult FDA resources for specifics. This page has not yet been medically reviewed.
Source: FDA; US federal law; DEA
Drug laws and enforcement change and vary by country. This is not legal advice. Always confirm with the destination’s embassy or official drug authority before traveling, because penalties can be severe, including imprisonment.
Before you travel
Verify current rules with the destination country’s official drug authority and your own country’s embassy before traveling. Find the destination’s U.S. embassy & official country guidance →
Non-U.S. travelers: check your own government’s travel advisory and embassy.
If you’re detained or arrested abroad
Contact your own country’s embassy or consulate in the destination immediately, not the destination’s authorities. U.S. citizens: contact the nearest U.S. embassy/consulate and the U.S. State Department at +1-202-501-4444 (from abroad). If a U.S. citizen is arrested or detained abroad →
Images
Visual references coming soon.
If it’s too intense
If an experience becomes overwhelming, the goal is to stay safe and let it pass, most difficult experiences ease as the drug wears off.
- Get to a calm, safe space with someone you trust who is sober and can stay with you.
- Cool down if you’re overheating, move somewhere cool, remove extra layers, rest. Overheating is especially a risk with stimulants and MDMA.
- Sip water to thirst, but don’t over-hydrate. Drinking large amounts of plain water (especially after MDMA) can dangerously dilute your blood sodium (hyponatremia). Electrolytes help more than volume.
- Slow your breathing, long, slow exhales help settle a racing heart and anxiety.
- A sugary drink, fruit juice, or a snack can ease shakiness and the anxiety that comes with low blood sugar.
- Do not take more, and do not add another substance to manage it. Redosing or adding something else (including a sedative like a benzodiazepine) can make things worse, not better.
Source: general harm-reduction guidance from SAMHSA, NIH/NIDA, and MedlinePlus, in our own words. Draft, not yet medically reviewed.
Forensic dossier
Draft · every field is source-cited or marked “Unknown, pending review”Identity
- PubChem CID
- 5002PubChem PUG-REST ↗ · retrieved 2026-06-18
- IUPAC name
- 2-[2-(4-benzo[b][1,4]benzothiazepin-6-ylpiperazin-1-yl)ethoxy]ethanolPubChem PUG-REST ↗ · retrieved 2026-06-18
- Molecular formula
- C21H25N3O2SPubChem PUG-REST ↗ · retrieved 2026-06-18
- SMILES
- C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42PubChem PUG-REST ↗ · retrieved 2026-06-18
- InChIKey
- URKOMYMAXPYINW-UHFFFAOYSA-NPubChem PUG-REST ↗ · retrieved 2026-06-18
- Synonyms / aliases
- seroquel, quetiapina, Norsic, quetiapinum, Quetiapine extended release, Seroquel XL, Tenprolide xl, Biquelle xl, Brancico xl, Mintreleq xl, Seotiapim xlPubChem PUG-REST + seed aliases ↗ · retrieved 2026-06-18
Composition
- Composition
- N/A — single compound (see Identity)
Physical / pill characteristics
- Dosage form
- 3 DOSAGE FORMS & STRENGTHS Quetiapine Tablets, USP 25 mg are Peach coloured, film coated, round shape, biconvex tablets, debossed with "262" on other side and popenFDA drug label ↗ · retrieved 2026-06-18
- Shape
- Unknown — pending review (verify tablet imprint/shape against NLM Pillbox/DailyMed; N/A if not an oral tablet)
- Color
- Unknown — pending review (verify tablet imprint/shape against NLM Pillbox/DailyMed; N/A if not an oral tablet)
- Imprint
- Unknown — pending review (verify tablet imprint/shape against NLM Pillbox/DailyMed; N/A if not an oral tablet)
- Score
- Unknown — pending review (verify tablet imprint/shape against NLM Pillbox/DailyMed; N/A if not an oral tablet)
Scheduling & legal status
- US schedule
- Unknown — pending review
- International
- Unknown, pending review
Effects, risks & interactions
- Effects
- Quetiapine is an atypical antipsychotic used for schizophrenia and bipolar disorder and, off-label, for sleep and anxiety; it acts on a range of receptors (dopamine, serotonin, histamine and others). It is not a recreational euphoriant or stimulant — its most prominent felt effect is strong sedation, especially at lower doses where its antihistamine action dominates, which is why it is misused as a sleep aid and in some institutional settings rather than for a "high." Any sought-after effect is sedation, not intoxication.PubChem CID 5002 + DailyMed Seroquel ↗ · retrieved 2026-06-18
- Risks
- Quetiapine's risks are those of a sedating antipsychotic rather than a party drug: pronounced drowsiness and next-day sedation, dizziness and a drop in blood pressure on standing (a falls risk), and — with regular use — significant metabolic effects including weight gain and raised blood sugar and lipids. It can prolong the heart's QT interval, and, as with all antipsychotics, it carries rare but serious risks (neuroleptic malignant syndrome; increased mortality in elderly people with dementia-related psychosis). In overdose it causes deep sedation, and that danger grows when it is combined with other CNS depressants.PubChem CID 5002 + DailyMed Seroquel ↗ · retrieved 2026-06-18
- Interactions
- Quetiapine is metabolised by the liver enzyme CYP3A4, so strong inhibitors of it (some antifungals and antibiotics) sharply raise quetiapine levels — the label advises a large dose reduction — while strong inducers lower them and can require a dose increase. Combined with other CNS depressants (alcohol, sedatives, opioids) its sedation is additive, and drugs that prolong the QT interval add to its cardiac risk.DailyMed Seroquel §7 ↗ · retrieved 2026-06-18
Pill catalog
Rx/OTC variants · openFDA + DailyMed (public domain) · draft, pending reviewThis drug comes in 327different versions. Make sure you’re looking at the right one, use the search above to find your exact pill by imprint, color, or shape.
Showing 24 of 327 variants
- Strength
- QUETIAPINE FUMARATE 300 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET, FILM COATED
- Labeler
- A-S Medication Solutions
- NDC
- 50090-3983 ↗ · 2026-06-18
- Strength
- QUETIAPINE FUMARATE 100 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET, FILM COATED
- Labeler
- Bryant Ranch Prepack
- NDC
- 63629-4776 ↗ · 2026-06-18
- Strength
- QUETIAPINE FUMARATE 200 mg/1
- Imprint
- 260
- Color
- WHITE
- Shape
- ROUND
- Form
- TABLET, FILM COATED
- Labeler
- Ascend Laboratories, LLC
- NDC
- 67877-246 ↗ · 2026-06-18
- Strength
- QUETIAPINE FUMARATE 300 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET, FILM COATED
- Labeler
- NuCare Pharmaceuticals,Inc.
- NDC
- 68071-1669 ↗ · 2026-06-18
- Strength
- QUETIAPINE FUMARATE 100 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET, FILM COATED
- Labeler
- REMEDYREPACK INC.
- NDC
- 70518-3429 ↗ · 2026-06-18
- Strength
- QUETIAPINE FUMARATE 400 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET, FILM COATED, EXTENDED RELEASE
- Labeler
- Major Pharmaceuticals
- NDC
- 0904-6805 ↗ · 2026-06-18
- Strength
- QUETIAPINE FUMARATE 150 mg/1
- Imprint
- 353
- Color
- YELLOW
- Shape
- ROUND
- Form
- TABLET, FILM COATED
- Labeler
- Ascend Laboratories, LLC
- NDC
- 67877-245 ↗ · 2026-06-18
- Strength
- QUETIAPINE FUMARATE 400 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET
- Labeler
- American Health Packaging
- NDC
- 60687-382 ↗ · 2026-06-18
- Strength
- QUETIAPINE FUMARATE 300 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET, FILM COATED
- Labeler
- Bryant Ranch Prepack
- NDC
- 71335-0772 ↗ · 2026-06-18
- Strength
- QUETIAPINE FUMARATE 25 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET
- Labeler
- : Preferred Pharmaceuticals Inc.
- NDC
- 68788-8764 ↗ · 2026-06-18
- Strength
- QUETIAPINE FUMARATE 300 mg/1
- Imprint
- XR 300
- Color
- YELLOW
- Shape
- CAPSULE
- Form
- TABLET, EXTENDED RELEASE
- Labeler
- AstraZeneca Pharmaceuticals LP
- NDC
- 0310-0283 ↗ · 2026-06-18
- Strength
- QUETIAPINE FUMARATE 150 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET, FILM COATED, EXTENDED RELEASE
- Labeler
- Direct_rx
- NDC
- 72189-586 ↗ · 2026-06-18
- Strength
- QUETIAPINE FUMARATE 400 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET, EXTENDED RELEASE
- Labeler
- Novast Laboratories, Ltd.
- NDC
- 34908-639 ↗ · 2026-06-18
- Strength
- QUETIAPINE FUMARATE 150 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET, EXTENDED RELEASE
- Labeler
- Novast Laboratories, Ltd.
- NDC
- 34908-636 ↗ · 2026-06-18
- Strength
- QUETIAPINE FUMARATE 200 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET, EXTENDED RELEASE
- Labeler
- Novast Laboratories, Ltd.
- NDC
- 34908-637 ↗ · 2026-06-18
- Strength
- QUETIAPINE FUMARATE 150 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET, FILM COATED, EXTENDED RELEASE
- Labeler
- Major Pharmaceuticals
- NDC
- 0904-6802 ↗ · 2026-06-18
- Strength
- QUETIAPINE FUMARATE 400 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET, FILM COATED
- Labeler
- REMEDYREPACK INC.
- NDC
- 70518-3933 ↗ · 2026-06-18
- Strength
- QUETIAPINE FUMARATE 300 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET, EXTENDED RELEASE
- Labeler
- Novast Laboratories, Ltd.
- NDC
- 34908-638 ↗ · 2026-06-18
- Strength
- QUETIAPINE FUMARATE 300 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET, FILM COATED
- Labeler
- Bryant Ranch Prepack
- NDC
- 71335-1709 ↗ · 2026-06-18
- Strength
- QUETIAPINE FUMARATE 50 mg/1
- Imprint
- 380
- Color
- pink
- Shape
- capsule
- Form
- TABLET, FILM COATED, EXTENDED RELEASE
- Labeler
- ACI Healthcare USA, Inc.
- NDC
- 71093-135 ↗ · 2026-06-18
- Strength
- QUETIAPINE FUMARATE 50 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET
- Labeler
- Preferred Pharmaceuticals, Inc.
- NDC
- 68788-8778 ↗ · 2026-06-18
- Strength
- QUETIAPINE FUMARATE 400 mg/1
- Imprint
- 384
- Color
- white
- Shape
- capsule
- Form
- TABLET, FILM COATED, EXTENDED RELEASE
- Labeler
- ACI Healthcare USA, Inc.
- NDC
- 71093-139 ↗ · 2026-06-18
- Strength
- QUETIAPINE FUMARATE 150 mg/1
- Imprint
- 381
- Color
- white
- Shape
- capsule
- Form
- TABLET, FILM COATED, EXTENDED RELEASE
- Labeler
- ACI Healthcare USA, Inc.
- NDC
- 71093-136 ↗ · 2026-06-18
- Strength
- QUETIAPINE FUMARATE 200 mg/1
- Imprint
- 382
- Color
- yellow
- Shape
- capsule
- Form
- TABLET, FILM COATED, EXTENDED RELEASE
- Labeler
- ACI Healthcare USA, Inc.
- NDC
- 71093-137 ↗ · 2026-06-18
Dosage
Pending medical reviewer
